Alfadda Assim A, Alzoghaibi Mohammed A
Department of Internal Medicine, College of Medicine and King Khalid University Hospital, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Saudi Med J. 2008 Apr;29(4):584-8.
To assess the effect of statins on the circulatory levels of neutrophil chemokines, namely, granulocyte chemotactic protein-2 GCP-2, growth regulated oncogene-alpha GRO-alpha and epithelial-cell-derived neutrophil-activating peptide-78 ENA-78 in patients with diabetes.
We studied 91 diabetic patients 46 were statin-treated and 45 were not and 28 healthy subjects. We measured the levels of GCP-2, GRO-alpha, and ENA-78 in the serum for the 3 groups using an enzyme linked immunosorbent assay. This cross-sectional study was conducted at King Khalid University Hospital KKUH, Riyadh, Kingdom of Saudi Arabia, from January 2006 to July 2007.
Circulating levels of GCP-2, ENA-78, and not GRO-alpha, were significantly higher in diabetic patients as compared to healthy subjects p<0.05. Statins dropped the levels of both GCP-2 and GRO-a. The ENA-78 levels were not affected by statin therapy. There was no correlation between the levels of these chemokines with the body mass index and glycemia in the population studied.
Diabetes is associated with an elevation of GCP-2 and ENA-78, and not GRO-alpha. Statins have a significant role in reducing the level of GCP-2.
评估他汀类药物对糖尿病患者中性粒细胞趋化因子循环水平的影响，即粒细胞趋化蛋白-2（GCP-2）、生长调节致癌基因-α（GRO-α）和上皮细胞衍生的中性粒细胞激活肽-78（ENA-78）。
我们研究了91例糖尿病患者（46例接受他汀类药物治疗，45例未接受治疗）和28名健康受试者。我们使用酶联免疫吸附测定法测量了三组血清中GCP-2、GRO-α和ENA-78的水平。这项横断面研究于2006年1月至2007年7月在沙特阿拉伯利雅得的哈立德国王大学医院（KKUH）进行。
与健康受试者相比，糖尿病患者的GCP-2、ENA-78循环水平显著升高（P<0.05），而GRO-α没有。他汀类药物降低了GCP-2和GRO-α的水平。ENA-78水平不受他汀类药物治疗的影响。在所研究的人群中，这些趋化因子的水平与体重指数和血糖之间没有相关性。
糖尿病与GCP-2和ENA-78升高有关，而与GRO-α无关。他汀类药物在降低GCP-2水平方面具有重要作用。
